Let’s Meet with Tech Hubs @ RESI NYC

~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Investor Research Analyst, LSN

The inaugural First Coast Innovator’s Gathering proved to be a big success at our September RESI, both for investors looking for the earliest stage companies and tech hubs wanting to gain exposure for their programs and constituents. Due to the positive reception, we are again featuring regional tech hubs at our upcoming RESI in NYC on November 5th. RESI NYC will feature tech hubs from New York and the surrounding states, including CT, RI, NJ and PA, bringing their constituents and displaying their technologies. In addition, tech hub constituents can apply to the Pitch Challenge for the chance to pitch to a panel of investors. Applications from the members of registered tech hubs will be accepted through Monday, October 15th, so don’t miss out on your chance!

Hot Investor Mandate: China-Based Biotech Company Seeking Global In-Licensing Opportunities in Oncology Indications with Potential for China Market

~ Next Phase Admin ~ Leave a comment

A biotech company founded in 2016 with several offices in China is VC backed with $150M Series A funding followed by $260 MM Series B funding. With immuno-oncology as the firm’s core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy. The company has a rich developing pipeline of oncology assets and is currently seeking in-licensing and partnership opportunities globally. The firm can invest in both private and public companies, depending on development stage of assets. The firm’s investment size depends on applicable deals.

The firm is particularly interested in first in class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy. The firm is currently focused on opportunities for the greater China market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Eastern USA-Based VC Firm Invests Up to $15M in Early-Stage Companies Working on Cancer Therapeutics & Regenerative Medicine

~ Next Phase Admin ~ Leave a comment

A venture capital firm based in Eastern USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the United States, Israel, and the United Kingdom.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Cross-Border Investment Firm in USA and China Seeks to Invest in Disruptive Medical Device Companies, Assisting Them With China Market Entry

~ Next Phase Admin ~ Leave a comment

A private investment firm with offices in USA and China is focused on medical device technologies. The firm is formed by pharmaceutical and medical device industry veterans and high-net-worth individuals with a committed capital of US$40 million. Typical investment size ranges from US $500K – 5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however, it can aid in identifying strategic partners in the Chinese market. The firm has expertise in helping portfolio companies in China Strategy, market strategy, regulatory strategy, and exit strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Invests in Medical Device and Digital Health Start-Ups Across All Indications

~ Next Phase Admin ~ Leave a comment

A venture capital company with offices in Eastern USA is currently making investments from its vintage 2013 fund and is looking to make equity investments into early stage medical devices and digital health companies. The firm’s investment size varies depending on the financial needs of the company and they generally participate in seed through series B rounds. To date, the firm has only made investments in companies throughout the United States though they are open to pursuing investments globally. The firm generally makes 1-2 new investment per year.

The firm is focused entirely on early stage medical devices and digital health. The firm is open to invest in all classes of medical devices and all indications and all areas of digital health. The firm generally looks to be the first round of institutional financing often investing in companies that have yet to fully develop their prototype. Companies the firm has invested in previously include devices for Orthopedics, Diagnostics, DNA Sequencing, Women’s Health, Diabetes, Imaging, and Active and Implantable Devices.

The firm is looking for companies whose market has barriers to entry, a quick path to proof of concept, and capital efficient operations. The firm looks for passionate founders and will evaluate management on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI NYC Partnering Launches on Monday – Are You Ready?

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, VP of Investor Research, LSN

It’s almost time to open RESI Partnering for the upcoming New York event on November 5th.  Hundreds of investors gathering to participate in RESI, and Partnering will run all day, providing entrepreneurs with up to 16 face to face meetings.

RESI’s unique partnering system includes detailed profiles sourced from investor interviews by LSN’s Investor Research team, and with this information attendees can direct their outreach to the attending investors who are the best fit for their technology, stage of development, and other relevant factors.  With this basis in fit, entrepreneurs can make relevant new connections at RESI and start dialogues with investors who could help take their product to the next stage.

Here’s a sampling of who you could meet in New York on November 5th.  We hope to see you again there.

Confirmed Investors & Strategic Partners

As of October 4th, 2018

Click to See More

Innovation Challenge Deadline Extended to Monday (10/8)

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Senior Research Analyst, LSN

claire

We can’t believe the RESI NYC Conference is only a month away! With this being our second year at NYC, the LSN team is truly excited about all of the innovation that we are gathering for the conference. We are particularly impressed by the global pool of applicants for the upcoming RESI NYC Innovation Challenge, with many startups from South America, Europe, the Middle East and Asia applying to be part of the Top 30 to showcase their technologies.

We have decided to extend the deadline to Monday, October 8th, to provide more time for startups who were interested in applying for this Innovation Challenge, but may not have had enough time to complete their applications. We are accepting submissions through our online application portal, and companies are also welcome to submit their application and supplementary materials to RESI@lifesciencenation.com.

Companies are selected based on multiple criteria, including the quality of the company’s scientific work, the strength of the management team and how well-positioned the company is to receive investment. We are impressed with the quality of the companies who we invite as Innovation Challenge finalists – we have seen as many as 50% of companies in an Innovation Challenge receive funding within one year of the conference.

Recently, we interviewed the first-place winner of our last Innovation Challenge at RESI Boston and you can read about his experience here. We also encourage interested applicants to read our recent article on how to be successful in the Innovation Challenge.

We hope you find these resources helpful, and we look forward to receiving your applications!